Working inthe Centauri lab

Revolutionising immunotherapy for the most vulnerable patients through our novel Alphamer® technology.

Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

Latest News and Articles

Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections

June 10, 2025

See attached press release

Read More
Pipettes

Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections

March 4, 2025

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique…

Read More
Scientist in lab

Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives

November 25, 2024

Centauri is excited to announce that we have been selected…

Read More